Bone Biologics Valuation
| BBLGW Stock | USD 20.20 0.00 0.00% |
At this time, the firm appears to be fairly valued. Bone Biologics Corp shows a prevailing Real Value of $19.39 per share. The current price of the firm is $20.2. Our model approximates the value of Bone Biologics Corp from analyzing the firm fundamentals such as Net Income of (4.11 M), number of shares shorted of 197, and Return On Equity of -1.29 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Bone Biologics' price fluctuation is relatively risky at this time. Calculation of the real value of Bone Biologics Corp is based on 3 months time horizon. Increasing Bone Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Bone stock is determined by what a typical buyer is willing to pay for full or partial control of Bone Biologics Corp. Since Bone Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bone Stock. However, Bone Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20.2 | Real 19.39 | Hype 20.2 |
The intrinsic value of Bone Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bone Biologics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bone Biologics Corp helps investors to forecast how Bone stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bone Biologics more accurately as focusing exclusively on Bone Biologics' fundamentals will not take into account other important factors: Bone Biologics Total Value Analysis
Bone Biologics Corp is currently forecasted to have takeover price of 0 with market capitalization of 0, debt of 377.71 K, and cash on hands of 4.44 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Bone Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 377.71 K | 4.44 K |
Bone Biologics Asset Utilization
One of the ways to look at asset utilization of Bone is to check how much profit was generated for every dollar of assets it reports. Bone Biologics Corp shows a negative utilization of assets of -0.69 percent, losing $0.00694 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Bone Biologics Corp shows how discouraging it operates for each dollar spent on its assets.Bone Biologics Profitability Analysis
Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0.About Bone Biologics Valuation
Our relative valuation model uses a comparative analysis of Bone Biologics. We calculate exposure to Bone Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bone Biologics's related companies.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.
Bone Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bone Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.5 M |
Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.